RGEN · Repligen Corp
Price
Snapshot
50 fields · last close| Market Cap | $9.46B |
| P/E | 227.70 |
| Float | 53.20M |
| Beta | 1.14 |
| Volatility | 28.6% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Mid cap |
| Macro sensitivity | Moderate |
| Clavix score | 68 |
| Price | 171.14 |
| Change | +2.11% |
| Prev Close | 167.60 |
| Open | 167.26 |
| Day Low | 165.00 |
| Day High | 169.51 |
| Avg Vol | 1 |
| Avg $ Vol | $165.9M |
| 52W High | 188.73 |
| 52W Low | 100.99 |
| 52W Pos | 80.0% |
| From High | −9.32% |
| From Low | +69.46% |
| Max DD 1Y | −40.28% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −1.19% |
| SMA 50 | +9.96% |
| SMA 200 | +20.54% |
| RSI (14) | 50.4 |
| Vol 30D | 49.2% |
| Vol 90D | 50.3% |
| 1Y Range | 101–189 |
| Daily bars | 507 |
| Perf Week | −4.92% |
| Perf Month | +5.12% |
| Perf Quarter | +37.03% |
| Perf Half Y | +39.68% |
| Perf Year | +38.99% |
| Perf YTD | +4.13% |
| Prev Day | +2.11% |
| Clavix | B- |
| Debt / Eq | 0.26 |
| Curr Ratio | 8.37 |
| Int Cover | -3.8× |
| FCF Margin | 14.0% |
| Rev Growth | +11.9% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 14 / 19 |
Clavix risk grade
regraded every trading dayRGEN grades B-, 68 of 100. Steadiest on News Sentiment (67), most exposed on Price Stability (49, fragile). 1 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 14 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| RGEN | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.14 | 1.19 |
| Volatilityannualized | 28.6% | 29.7% |
| Max drawdown, past yearworst peak-to-trough fall | −40.3% | — |
| Typical daily movemedian absolute daily change | 1.65% | — |
| Days beyond ±3%of the last 252 sessions | 6425% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| RGEN | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.14 | 1.19 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| RGEN | |
|---|---|
| 1 week | −4.9% |
| 1 month | +5.1% |
| Year to date | +4.1% |
| 1 year | +39.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| RGEN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 22 Jul |
| Average score0 most bearish, 100 most bullish | 68 |
| Bullish · bearisharticles above 60 · below 40 | 26 · 4 |
| Directionarticles whose tone is improving vs worsening | 26 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| RGEN | |
|---|---|
| Revenue growthyear over year | +11.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Life Sciences Tools & Services
19 companies| Metric | RGEN | Sector spread | Median |
|---|---|---|---|
| Beta | 1.14 | 1.19 | |
| Volatility | 28.6% | 29.7% | |
| P/E | 227.70 | 36.46 | |
| Debt / equity | 0.26 | 0.51 | |
| Current ratio | 8.37 | 1.89 | |
| FCF margin | 14.0% | 18.8% | |
| Interest coverage | -3.8× | 3.5× |
Recent news
most recent scored articles · the chip is the article’s score · click to openModerna and Merck's personalized mRNA cancer vaccine, given alongside Merck's Keytruda, successfully extended the time high-risk melanoma patients stayed cancer-free after surgery in a 1,137-person Phase 3 trial, sending Moderna's stock up more than 60%. The article highlights that making each custom dose requires sequencing the patient's tumor, running bioinformatics, and specialized manufacturing consumables, drawing renewed investor interest in companies that supply those tools, including Tempus, Personalis, Illumina, and Repligen.
The article notes that a DCF estimate (a method that calculates what a company's future cash is worth in today's dollars) is near the current share price, while market-based valuation multiples (ratios like price-to-sales) suggest the stock looks more expensive.
United Capital Financial Advisors LLC disclosed a new position in Repligen Corporation, buying 2,790,650 shares worth about $380.76 million during the second quarter, according to its SEC filing. The article body provides no further detail about the fund's reasoning or any company-specific news.
Repligen is purchasing BioLife Solutions for $1.5 billion, adding CryoStor biopreservation technology to its bioprocessing portfolio, reflecting the pharmaceutical industry's shift toward integrated cell and gene therapy supply chains.
Zacks Research upgraded Repligen (NASDAQ:RGEN) from a 'hold' rating to a 'strong-buy' rating in a research report released on Thursday. The article provides no additional details on the rationale behind the upgrade.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| QGEN | Qiagen NV | B+ | $8.96B | 21.89 | 0.60 | Compare |
| BRKR | Bruker Corp | C- | $8.91B | — | 1.26 | Compare |
| AVTR | Avantor Inc | B- | $10.13B | — | 0.98 | Compare |
| TXG | 10X Genomics Inc | C- | $8.16B | — | 2.07 | Compare |
| TECH | Bio-Techne Corp | B- | $11.36B | 62.46 | 1.30 | Compare |
| TEM | Tempus AI Inc | D- | $11.66B | — | 2.33 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $13.77B | — | 1.41 | Compare |
| RVTY | Revvity Inc | B | $14.53B | 61.17 | 1.11 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.